ESPR vs. RVNC, AMRN, LXRX, NATR, MREO, ADCT, MRSN, BMEA, HROW, and CRBP
Should you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Revance Therapeutics (RVNC), Amarin (AMRN), Lexicon Pharmaceuticals (LXRX), Nature's Sunshine Products (NATR), Mereo BioPharma Group (MREO), ADC Therapeutics (ADCT), Mersana Therapeutics (MRSN), Biomea Fusion (BMEA), Harrow Health (HROW), and Corbus Pharmaceuticals (CRBP). These companies are all part of the "pharmaceutical preparations" industry.
Esperion Therapeutics (NASDAQ:ESPR) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.
47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 97.7% of Revance Therapeutics shares are owned by institutional investors. 1.0% of Esperion Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Revance Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Esperion Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.
Esperion Therapeutics has higher earnings, but lower revenue than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Esperion Therapeutics had 11 more articles in the media than Revance Therapeutics. MarketBeat recorded 15 mentions for Esperion Therapeutics and 4 mentions for Revance Therapeutics. Revance Therapeutics' average media sentiment score of 0.48 beat Esperion Therapeutics' score of -0.12 indicating that Revance Therapeutics is being referred to more favorably in the news media.
Esperion Therapeutics received 202 more outperform votes than Revance Therapeutics when rated by MarketBeat users. Likewise, 69.74% of users gave Esperion Therapeutics an outperform vote while only 63.92% of users gave Revance Therapeutics an outperform vote.
Revance Therapeutics has a net margin of -138.43% compared to Esperion Therapeutics' net margin of -179.87%.
Esperion Therapeutics presently has a consensus target price of $9.33, indicating a potential upside of 348.72%. Revance Therapeutics has a consensus target price of $13.75, indicating a potential upside of 248.10%. Given Esperion Therapeutics' higher possible upside, equities research analysts clearly believe Esperion Therapeutics is more favorable than Revance Therapeutics.
Summary
Revance Therapeutics beats Esperion Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Esperion Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Esperion Therapeutics Competitors List
Related Companies and Tools
